



Deposited via The University of York.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/132063/>

Version: Accepted Version

---

**Article:**

Lloyd, Charlie, Hamilton, Ian and Monaghan, Mark (2018) Rising numbers of older and female cannabis users seeking treatment in England and Wales. *Drugs: education, prevention and policy*. pp. 205-207. ISSN: 1465-3370

<https://doi.org/10.1080/09687637.2018.1478948>


---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**


If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.




**Rising numbers of older and female cannabis users seeking treatment in England and Wales.**

Journal:	<i>Drugs: Education, Prevention &amp; Policy</i>
Manuscript ID	CDEP-2018-0006.R2
Manuscript Type:	Short report
Keywords:	Cannabis, older, female, Treatment

SCHOLARONE™  
Manuscripts





Peer Review Only

1  
2  
3  
4 Rising numbers of older and female cannabis users seeking treatment in England and Wales.  
5  
6  
7

8 Abstract  
9

10 Presentations to specialist drug treatment services in England for cannabis have been rising in  
11 recent years. As cannabis is no longer disaggregated in annual reports of drug treatment  
12 presentations published by Public Health England, we requested access to a detailed data-set  
13 to explore the treatment population in more detail. Analysis of the data revealed two  
14 important issues which were not apparent in the published reports. Males and females over  
15 the age of forty are a rapidly growing sub-group. This reflects the parallel growth in those in  
16 treatment primarily for problems due to opiates.  
17  
18  
19

20 Keywords: Cannabis, older, female, treatment  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Rising numbers of older and female cannabis users seeking treatment in England and Wales.**

### **Introduction**

Cannabis continues to be the most popular illicit drug in the United Kingdom and Europe, with 2.2 and 23.5 million adults respectively having used the drug in the last year (Home Office 2017, EMCDDA 2017). Up to 70% of those trying and using cannabis will not develop a dependency that requires treatment (Hasin et al 2015). However some will require help and support as a result of developing dependence, commencing cannabis use before the age of eighteen and being male are two factors that increase the risk of developing dependence (Copeland and Swift, 2009). Presentations to treatment services where cannabis is cited as the primary problem drug have been rising in England over recent years, although several factors are thought to have led to this increase in demand such as increasing potency of cannabis, net widening by treatment services as they accept requests for help from individuals who report problems as a result of using cannabis (Hamilton et al 2014, McCulloch 2017).

### **Methods**

As cannabis is no longer disaggregated in annual reports of drug treatment presentations published by Public Health England, we requested access to a detailed data-set to explore the treatment population in more detail.

The data Public Health England provided detail in relation to gender and age, recorded age spanned from 18 to 60 plus with age intervals provided in bandings of four years, for example 20-24 years old. Two categories of cannabis assessment were included the first was where cannabis was cited on assessment the second where cannabis was recorded as the primary drug problem.

The data covers England and Wales and includes all new presentations to specialist drug treatment services between 2005/06 and 2015/16. Total presentations varies annually, 2006/07 recorded the lowest total with 108,638 new presentations and 2008/09 the highest with 147,578.

A simple analysis of the data was performed by exploring trends in age of presentation for cannabis by year and then by gender for these groups, this revealed two important issues which were not apparent in the published reports.

### **Results**

#### **Age**

This new data set shows that, although there has been an increase in presentations for cannabis as the only drug problem across the whole adult age range, the rise in those over the age of 40 years old is more marked. 471 people presented in 2005/06 but by 2015/16 this had risen to 1008, an increase of 114%. Over the same period presentations for all drugs in those aged 40 or older increased by 137% from 27,092 in 2005/06 to 64,195 in 2015/16.

1  
2  
3 By contrast those aged 39 and under showed a 53.4% increase over the same period in time,  
4 however this age group still account for the majority of these presentations with 5,879 in  
5 2015/16. Overall presentations for all drugs for those aged 39 and under decreased by 12%  
6 from 83,595 in 2005/06 to 73,886 in 2015/16.  
7  
8  
9

10 Figure 1 Presentations to treatment where cannabis is the primary problem aged 40 and over.  
11  
12

13 The rising number of older people presenting to treatment for cannabis suggests the need for  
14 a greater focus on older users. In the United Kingdom the majority of people who use  
15 cannabis are thought to combine it with tobacco (Hindocha et al 2016). It is therefore likely  
16 that this older cohort of cannabis users will be at greater risk of developing the range of  
17 health problems associated with prolonged tobacco exposure (Meier et al 2016).  
18  
19

20 As cannabis potency has increased over the same time period it is possible that all age cohorts  
21 have increasingly experienced problems and this could have contributed to the rise in  
22 treatment presentations (Montanari et al 2017). The comparatively greater rise in those aged  
23 forty and over might be explained by changing market supply over recent years from  
24 comparatively weak cannabis 'resin', to newer, stronger strains of herbal cannabis, with  
25 accompanying problems of titrating dosage and eventual appearance in drug treatment  
26 (Freeman and Winstock 2015).  
27  
28

### 29 **Gender**

30 Further analysis of the data shows the gender ratio for those who cite cannabis as their only  
31 drug problem is just under 3:1 in favour of males, however this gender ratio widens to 4:1 for  
32 those in treatment citing cannabis as one of several drugs they have problems with. Over the  
33 last decade there has been a 95% increase in the number of females citing cannabis as the  
34 only problem drug, compared to a 72% increase for males. Traditionally treatment services  
35 have been populated and designed for men (Wincup 2016). This suggests change in treatment  
36 design and delivery is required to cater specifically for the rise in female presentations. There  
37 is increasing evidence and calls for treatment services to tune into the needs of women who  
38 are likely to have experienced trauma such as intimate partner violence (Gilchrist and  
39 Hegarty 2017).  
40  
41  
42  
43  
44

45 Figure 2 Presentations to treatment by gender  
46  
47

### 48 **Discussion**

49 Overall demand for treatment where cannabis is cited as the primary problem has increased  
50 over the last decade. The majority of the rise is accounted for by males under the age of forty.  
51 However further analysis of the PHE data reveals a significant rise in those age forty or over.  
52 Also a marked rise in female presentations of all ages has taken place over the same time  
53 period.  
54

55 It is worth noting that the last decade has seen a decline in reported cannabis use for the  
56 general population. The crime survey estimates 2.2 million people used cannabis in 2005/06  
57  
58  
59

1  
2  
3 this fell to 1.4 million by 2015/16. So the rise in females and those aged forty or over  
4 presenting to treatment could in part be accounted for a time lag between initiating cannabis  
5 use and developing problems with the drug which prompt individual treatment presentations.  
6

7 The higher risk of treatment presentation for males than females can in part be explained by  
8 the greater number of males using cannabis than females. However it is likely that factors  
9 other than cannabis use influence treatment presentation. There are well documented reasons  
10 why females might avoid treatment or at least consider that specialist drug treatment is not a  
11 safe option for them (Salter and Breckenridge 2014).  
12

13 Treatment services have faced two significant changes over the last decade, first funding for  
14 drug treatment in England and Wales has been reduced. Secondly fewer people have  
15 developed problems with opiates which has reduced demand for treatment from this group. It  
16 is possible that treatment services have responded to this fall in demand by accepting and  
17 treating more of those with cannabis problems (Hamilton et al 2014).  
18  
19

## 20 Conclusion

21 This data suggests that the majority of people seeking treatment for cannabis are male and  
22 aged under forty. However males and females over the age of forty are a rapidly growing  
23 sub-group. This reflects the parallel growth in those in treatment primarily for problems due  
24 to opiates, this group develop complex co-morbidities which require referral to specialist  
25 physical and mental health treatment providers, it is not clear if this also applies to the ageing  
26 cohort of cannabis users who are presenting in increasing numbers to specialist drug  
27 treatment.  
28  
29

30 These findings suggest that further investigation is required, first to explore this ageing cohort  
31 This ageing cohort warrants further investigation to try and understand what their specific  
32 problems they have experienced are, their reasons for entering treatment and investigate how  
33 effective that treatment they receive is. Secondly, as we found that female presentations had  
34 increased significantly it would also be useful to explore their specific problems in relation to  
35 cannabis and how treatment services respond to these needs. Finally research which  
36 investigates cannabis treatment presentations in other countries would provide a broader  
37 insight into other populations and treatment uptake.  
38  
39

## 40 References:

41  
42 Copeland, J. and Swift, W., (2009). Cannabis use disorder: epidemiology and  
43 management. *International Review of Psychiatry*, 21(2), pp.96-103.  
44

45 European Monitoring Centre for Drugs and Drug Addiction, (2017) Statistical bulletin 2017.  
46 [http://www.emcdda.europa.eu/data/stats2017\\_en](http://www.emcdda.europa.eu/data/stats2017_en) (Accessed 14/12/17).  
47

48 Freeman, T.P. and Winstock, A.R., 2015. Examining the profile of high-potency cannabis  
49 and its association with severity of cannabis dependence. *Psychological medicine*, 45(15),  
50 pp.3181-3189.  
51

52 Gilchrist, G. and Hegarty, K., 2017. Tailored integrated interventions for intimate partner  
53 violence and substance use are urgently needed. *Drug and alcohol review*, 36(1), pp.3-6.  
54

55 Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United  
56 States Between 2001-2002 and 2012-2013. *JAMA Psychiatry*. 2015;72(12):1235-1242.  
57  
58

- 1  
2  
3 Hamilton, I., Lloyd, C., Monaghan, M., & Paton, K. (2014). The emerging cannabis  
4 treatment population. *Drugs and Alcohol Today*, 14(3), 150-153.
- 5  
6 Hindocha, C., Freeman, T.P., Ferris, J.A., Lynskey, M.T. and Winstock, A.R., (2016). No  
7 smoke without tobacco: a global overview of cannabis and tobacco routes of administration  
8 and their association with intention to quit. *Frontiers in psychiatry*, 7.
- 9  
10 Home Office (2017). Drug misuse: findings from the 2016 to 2017 CSEW. National Statistics  
11 <https://www.gov.uk/government/statistics/drug-misuse-findings-from-the-2016-to-2017-csew>  
12
- 13 Johnston, Lidell, D. Browne, K. Priyadarshi, S. (2017). Responding to the needs of ageing  
14 drug users. European Monitoring Centre for Drugs and Drug Addiction  
15 [http://www.emcdda.europa.eu/document-library/responding-needs-ageing-drug-users\\_en](http://www.emcdda.europa.eu/document-library/responding-needs-ageing-drug-users_en)  
16
- 17 McCulloch, L. (2017). Why did cannabis treatment presentations rise in England from 2004-  
18 2005 to 2013-2014?. *Drugs and Alcohol Today*, 17(4), pp.218-231.
- 19  
20 Meier, M.H., Caspi, A., Cerdá, M., Hancox, R.J., Harrington, H., Houts, R., Poulton, R.,  
21 Ramrakha, S., Thomson, W.M. and Moffitt, T.E., (2016). Associations between cannabis use  
22 and physical health problems in early midlife: a longitudinal comparison of persistent  
23 cannabis vs tobacco users. *JAMA psychiatry*, 73(7), pp.731-740.
- 24  
25 Monaghan, M., Hamilton, I., Lloyd, C., & Paton, K. (2016). Cannabis matters? Treatment  
26 responses to increasing cannabis presentations in addiction services in England. *Drugs:*  
27 *Education, Prevention and Policy*, 23(1), 54-61.
- 28  
29 Montanari, L., Guarita, B., Mounteney, J., Zipfel, N. and Simon, R., (2017). Cannabis Use  
30 among People Entering Drug Treatment in Europe: A Growing Phenomenon. *European*  
31 *Addiction Research*, 23(3), pp.113-121.
- 32  
33 Salter, M. and Breckenridge, J., (2014). Women, trauma and substance abuse: Understanding  
34 the experiences of female survivors of childhood abuse in alcohol and drug  
35 treatment. *International Journal of Social Welfare*, 23(2), pp.165-173.
- 36  
37 Wincup, E., (2016). Gender, recovery and contemporary UK drug policy. *Drugs and Alcohol*  
38 *Today*, 16(1), pp.39-48.
- 39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60